Abbott Receives Health Canada’s Approval for Esprit BTK System to Treat Chronic Limb Threatening Ischemia Below the Knee

Shots:Abbott has received Health Canada’s approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System to treat people with chronic limb-threatening ischemia (CLTI) below the knee (BTK)Esprit was evaluated in the LIFE-BTK trial against balloon angioplasty, which showed improved patient outcomes, with 48% fewer repeat procedures over the study period. Data was highlighted…

ByRidhi RastogiOctober 1, 2025

NEWS

Abbott’s Navitor TAVI System Receives European CE Mark for Aortic Stenosis in Patients at Low or Intermediate-Risk for Surgery

Shots:Abbott has received the CE Mark approval for Navitor transcatheter aortic valve implantation(TAVI) system to expand its use in people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgeryApproval was backed by VANTAGE study of Navitor TAVI, which met its safety & efficacy 1EPs in above ptsTrial showed…

ByRidhi RastogiSeptember 1, 2025

NEWS

Abbott Receives the European CE Mark for Esprit BTK System to Treat Peripheral Artery Disease Below the Knee

Shots:Abbott has received European CE Mark approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System to treat people with peripheral artery disease (PAD) below the knee (BTK)Esprit was evaluated in the LIFE-BTK trial against balloon angioplasty in pts (n >260) with PAD BTK, which showed sustained efficacy & ability to open vessels…

ByRidhi RastogiAugust 27, 2025

NEWS

Abbott Reports the Approval for its Denosumab Biosimilar in Thailand

Shots: Abbott has secured regulatory approval for its denosumab biosimilar in Thailand, increasing access to advanced treatments for osteoporosis and cancer-related bone loss Denosumab is a mAb that works by targeting RANKL, which regulates bone metabolism & osteoclast formation Abbott will offer denosumab as part of its strategy to expand access to quality medicines in…

ByDipanshu DixitAugust 26, 2025

VIEWPOINTS

Patient Insights: Jerry Kelleher in an Illuminating Conversation with PharmaShots

Shots: Abbott’s AVEIR DR is the first in the world dual-chamber leadless pacemaker Jerry Kelleher, a clinical trial participant in the AVEIR DR study, shares his transformative journey with PharmaShots Explore Jerry’s miraculous recovery with AVEIR DR, which helped enhance his quality of life Saurabh: Jerry, can you take us back to life and describe…

BySaurabh ChaubeyJuly 7, 2025

NEWS

Abbott Secures European CE Mark for Volt PFA System to Treat Atrial Fibrillation

Shots:Abbott has received European CE Mark for its Volt PFA System to treat pts with atrial fibrillation; commercialization has begun, with further expansion in EU markets expected by H2’25Approval was based on CE Mark study in the EU & Australia, showing that the Volt achieved pulmonary vein isolation (PVI) in 99.1% veins with…

ByRidhi RastogiMarch 28, 2025

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2024

Shots:The second quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Vertex’ acquisition of Alpine Immune Sciences for ~$4.9BThis quarter also showcased multiple clinical trial results including Moderna’s P-III Study Data of mRNA-1283 Vaccine to Prevent COVID-19…

BySenior EditorJuly 2, 2024

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2024

Shots:The first quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Gilead's acquisition of CymaBay Therapeutics for an aggregate of ~$4.3BThis quarter also showcased multiple clinical trial results including Axsome Therapeutics P-III results for AXS-12 and BMS'…

BySenior EditorApril 1, 2024

INSIGHTS+

Insights+: The US FDA New Drug Approvals in November 2023

Shots: The US FDA approved 5 NDAs & 4 BLAs in November 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 109 novel products in 2023 In November 2023, the major highlights drugs were Wezlana (ustekinumab) approved for Multiple Inflammatory Diseases, and Cosentyx (secukinumab) for the Treatment…

BySenior EditorDecember 20, 2023

VIEWPOINTS

Matthew G. Fishler Shares the Highlights of AVEIR DR, the World’s First Dual-Chamber Leadless Pacemaker System

Shots: Matthew G. Fishler, Chief Engineer and Director of Product Development Abbott’s Cardiac Rythm Management Business, in an insightful conversation with PharmaShots Matthew shares the highlights of the recently approved AVEIR Dr, the world’s first dual-chamber leadless pacemaker system for patients with slower-than-normal or abnormal heart rhythms Equipped with i2i™ communication technology, AVIER DR eliminates…

BySaurabh ChaubeyNovember 20, 2023

Abbott Receives Health Canada’s Approval for Esprit BTK System to Treat Chronic Limb Threatening Ischemia Below the Knee

Abbott’s Navitor TAVI System Receives European CE Mark for Aortic Stenosis in Patients at Low or Intermediate-Risk for Surgery

Abbott Receives the European CE Mark for Esprit BTK System to Treat Peripheral Artery Disease Below the Knee

Abbott Reports the Approval for its Denosumab Biosimilar in Thailand

Patient Insights: Jerry Kelleher in an Illuminating Conversation with PharmaShots

Abbott Secures European CE Mark for Volt PFA System to Treat Atrial Fibrillation

PharmaShots’ Key Highlights of Second Quarter 2024

PharmaShots’ Key Highlights of First Quarter 2024

Insights+: The US FDA New Drug Approvals in November 2023

Matthew G. Fishler Shares the Highlights of AVEIR DR, the World’s First Dual-Chamber Leadless Pacemaker System

Contact US

OUR INFORMATION

FOLLOW US